Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of the study is to assess the safety and efficacy of two doses of IV palonosetron each administered as a single dose for the prevention of postoperative nausea and vomiting through 72 hours postoperatively in children aged 28 days up to 16 years inclusive undergoing surgical procedures requiring general endotracheal inhalation anesthesia.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 mcg/kg arm | Experimental | Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg) |
|
| 3 mcg/kg arm | Experimental | Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| palonosetron | Drug | palonosetron IV 1 mcg/kg |
| |
| palonosetron |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively | 0-72 hours post-operatively |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Patients With Complete Response 0-24 Hours | Complete Response defined as no vomiting, no retching, and no use of rescue medication | 0-24 hours |
Not provided
MAIN INCLUSION CRITERIA
Male or female patient aged more than 28 days (full term) up to and including 16 years.
Inpatient scheduled to undergo surgical procedures requiring general endotracheal anesthesia, including:
American Society of Anesthesiologists (ASA) physical status I, II or III.
Patient scheduled to receive nitrous oxide during the maintenance phase of anesthesia.
Patient scheduled to be hospitalized for at least 72 hours after wake up of surgery
For female of childbearing potential: the patient and her parent(s)/legal guardian(s) were counseled on the importance of not becoming pregnant before or during the study and the patient must have a negative pregnancy test at the pre-treatment visit and at the study treatment visit.
MAIN EXCLUSION CRITERIA
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Federal State Institution Central Research Institute of Traumatology and Orthopedics n.a. N.N. Priorov under the Federal Agency for High-Tech Medical Care | Moscow | Russia |
Not provided
First patient enrolled: 19 August 2008. Last patient completed: 27 December 2008.
A total of 12 Investigators from two countries (Russia and Ukraine) participated in the study. The study was conducted at 4 sites in Russia and 8 sites in Ukraine.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 1 mcg/kg Arm | Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg) palonosetron: palonosetron IV 1 mcg/kg |
| FG001 | 3 mcg/kg Arm | Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg) palonosetron: palonosetron 3mcg/kg IV |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
palonosetron 3mcg/kg IV |
|
| Federal State Institution Moscow Research Institute of Pediatrics and Pediatric Surgery under the Federal Agency for High-Tech Medical Care | Moscow | Russia |
| Federal State Institution St. Petersburg Research Institute of Ear, Throat, Nose and Speech under the Federal Agency for High-Tech Medical Care | Saint Petersburg | Russia |
| State Higher Educational Institution: "St. Petersburg State Pediatric Medical Academy under the Federal Agency for Healthcare and Social Development" | Saint Petersburg | Russia |
| State Healthcare Institution 'Regional Pediatric Clinical Hospital' | Yaroslavl | Russia |
| Cherkassy Regional Hospital, Pediatric Surgery Department | Cherkassy | Ukraine |
| Regional Children's Clinical Hospital. Dnipropetrovsk State Medical Academy, Pediatric Surgery Department | Dnipropetrovsk | Ukraine |
| M.Gorkyi Donetsk National Medical University, Pediatric Surgery Department; Children's Regional Clinical Hospital | Donetsk | Ukraine |
| Regional Children's Hospital, ENT Department, Ivano-Frankivsk State Medical University, ENT Department | Ivano-Frankivsk | Ukraine |
| Specialized Children's Hospital "OKHMATDYT", Orthopedics and Traumatology Department, O.O. Bohomolets National Medical University, Pediatric Surgery Department | Kyiv | Ukraine |
| Ukrainian Specialized Children's Hospital "OKHMATDYT", Anesthesiology and Intensive Care Department, P.L. Shupyk National Medical Academy of Postgraduate Education, Pediatric Anesthesiology and Intensive Care Department | Kyiv | Ukraine |
| Ukrainian Specialized Children's Hospital "OKHMATDYT", ENT Department, P.L. Shupyk National Medical Academy of Postgraduate Education, Pediatric ENT Department | Kyiv | Ukraine |
| Children's Clinical Hospital "OKHMATDYT", Institute of Congenital Pathology under the Academy of Medical Sciences of Ukraine | Lviv | Ukraine |
| COMPLETED |
|
| NOT COMPLETED |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 1 mcg/kg Arm | Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg) palonosetron: palonosetron IV 1 mcg/kg |
| BG001 | 3 mcg/kg Arm | Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg) palonosetron: palonosetron 3mcg/kg IV |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number | participants |
| |||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| |||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Patients With no Emetic Episodes in the Overall Time Period 0-72 Hours Post-operatively | The Full Analysis Set (FAS) included all randomized patients, who received the study drug, had general anesthesia and surgery. Following the intent-to-treat principle, patients were assigned to the study treatment group according to the treatment to which they were randomized. | Posted | Number | 95% Confidence Interval | percentage of patients | 0-72 hours post-operatively |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Proportion of Patients With Complete Response 0-24 Hours | Complete Response defined as no vomiting, no retching, and no use of rescue medication | Full Analysis Set | Posted | Number | 95% Confidence Interval | percentage of patients | 0-24 hours |
|
|
During the study, all adverse events were recorded and Patients stayed in the study for 22 days as a maximum. Duration of the safety follow up was 14 days after the patient completed the study for non Serious adverse events.
Serious AEs were followed up until resolution/or reached a stable condition/or until subject lost to follow-up, Safety Set/SAF included all randomized patients assigned to treatment group according to actual treatment received. SAF had 74 and 76 patients/1 mcg/kg 3 mcg/kg group respectively/since one patient randomized 1 mcg/kg was treated 3 mcg/kg
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 1 mcg/kg Arm | Single dose IV Palonosetron 1 mcg/kg (up to a maximum total dose of 0.075 mg) palonosetron: palonosetron IV 1 mcg/kg | 0 | 74 | 29 | 74 | ||
| EG001 | 3 mcg/kg Arm | Single dose IV Palonosetron 3 mcg/kg (up to a maximum total dose of 0.25 mg) palonosetron: palonosetron 3mcg/kg IV | 0 | 76 | 32 | 76 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Procedural pain | Injury, poisoning and procedural complications | MedDRA 14.0 | Systematic Assessment |
| |
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Rhinalgia | Respiratory, thoracic and mediastinal disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Asthenia | General disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Nausea | Gastrointestinal disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Dizziness | Nervous system disorders | MedDRA 14.0 | Systematic Assessment |
| |
| Nasopharyngitis | Infections and infestations | MedDRA 14.0 | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Salvatore Chessari | Helsinn Healthcare SA | +41 91 985 21 21 | salvatore.chessari@helsinn.com |
| ID | Term |
|---|---|
| D020250 | Postoperative Nausea and Vomiting |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009325 | Nausea |
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D014839 | Vomiting |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077924 | Palonosetron |
| ID | Term |
|---|---|
| D011812 | Quinuclidines |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006571 | Heterocyclic Compounds |
| D007546 | Isoquinolines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
Not provided
Not provided
| Title | Measurements |
|---|---|
|
| 6 to <12 years |
|
| 12 to <17 years |
|
| Male |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| Russian Federation |
|
|